ZGNX guaranteed success on Dravet Syndrome to be r

ZGNX guaranteed success on Dravet Syndrome to be released in September. This drug has been proven safe and effective for a decade in Belgium. Pot stock GWPH is worth 2.5 Billion for the same indication, while Zogenix is mistakenly only 1/10 of that. Short term can sell $16-18, Long term sell above $24 which is the current price-target average from brokers. This company may be bought-out after results. Their management has a consistent habit of finding, improving and selling pharma stocks. One look at the improved Market Cap proves it yet again for these fellas.